Insulet’s Omnipod 5 Insulin Pump App Receives FDA Approval

In a triumph for diabetes management technology, Insulet, a leading provider of tubeless insulin delivery systems, celebrates a major milestone in their product line. The recently approved iPhone app for controlling the Omnipod 5 insulin pump marks a groundbreaking advancement in diabetes care, affirming Insulet's commitment to enhancing the lives of individuals with diabetes.

Eric Benjamin, Chief Product and Customer Experience Officer at Insulet, hailed the app's launch as a "significant milestone" in their ongoing mission to provide innovative solutions that alleviate the burden of diabetes management. This achievement is particularly noteworthy as it empowers users to streamline their treatment regimen and reduce the need for carrying additional devices.

Become a Subscriber

Please purchase a subscription to continue reading this article.

Subscribe Now

The Omnipod 5 app offers users a comprehensive suite of features, allowing them to set up the system, configure new insulin pods, adjust insulin delivery settings, and administer or cancel bolus doses directly from their smartphone. When coupled with a continuous glucose monitor, the app facilitates automated insulin delivery, creating a seamless closed-loop system for diabetes care.

One standout feature of the iOS version is the inclusion of Custom Foods, enabling users to store carbohydrate counts for their most frequently consumed foods. These counts can be seamlessly integrated into the SmartBolus calculator, simplifying mealtime dosing and enhancing overall convenience.

Initially, the iPhone app will be available exclusively to Omnipod 5 customers utilizing Dexcom G6 Continuous Glucose Monitors (CGMs), with plans for a broader market release in the coming year. Following its launch, users can download the app free of charge from the Apple App Store and seamlessly sync it with their Omnipod 5 system.

Insulet is also diligently working on customizing the Omnipod 5 to accommodate Dexcom's highly anticipated G7 glucose sensor, showcasing their commitment to staying at the forefront of diabetes care technology.

This recent development solidifies Insulet's position as a pioneer in the field, as they become the first company to offer a tubeless automated insulin administration device entirely controllable via Android or Apple smartphones. While other industry leaders like Medtronic and Tandem Diabetes Care have introduced smartphone apps for their insulin pumps, they still rely on traditional infusion set tubing, setting Insulet's innovation apart.

With further developments on the horizon, the future looks promising for individuals living with diabetes and seeking more convenient and effective solutions for their health and well-being.